15-year EVAR 1 follow up – benchmark for newer technologies

Roger Greenhalgh

Imperial College London

Disclosure

Speaker name:

Roger Greenhalgh

I have the following potential conflicts of interest to report:

- ☐ Consulting
- ☐ Employment in industry
- ☐ Stockholder of a healthcare company
- ☐ Owner of a healthcare company
- ☐ Other(s)

- ☒ I do not have any potential conflict of interest

Individual Patient Data meta-analysis (IPD)

Combines actual results of EVAR, DREAM, ACE and OVER

Supported by all 4 trial management committees and principal investigators

- **DREAM – Jan Blankensteijn**
- **ACE – Jean-Pierre Becquemin**
- **OVER – Frank Lederle**

Datasets at Charing Cross, Imperial College
Statistical analysis at University of Cambridge

Follow-up of 4 RCTs



IPD

The length of follow up for each study:

EVAR 1	**15 years**
DREAM	**6 years**
ACE	**3 years**
OVER	**9 years**

The mean follow-up time to be used for the meta-analysis is 4.7 years

The common variables are to be chosen from the following but have not yet been finalised:
Age, sex, BMI, diabetes, smoking history, ABPI (except ACE), creatinine,
previous history of angina/MI, max AAA diameter, AAA neck diameter and AAA neck length.

EVAR 15 year follow-up

Primary objective: Aneurysm related mortality
Secondary objectives: All-cause mortality, complications and re-interventions, secondary rupture rates and costs.

We obtained the follow up for 68% of patients with EVAR and 34% with Open Repair

Hospital Episode Statistics (HES) data has been obtained in 663 patients with EVAR 1

EVAR Trial 1


1252
TOTAL
626
EVAR
626
open repair
2009
365
EVAR still alive
361
open repair still alive


EVAR
Local follow-up
250 (68%)
Still alive without
follow-up 28 (8%)
Dead without
follow up 87 (24%)

Open Repair


Local follow-up 123 (34%)
Alive without follow-up 94 (26%)
Dead without follow up 144 (40%)

Aneurysm-related mortality



Effect of evidence that EVAR works

European Vascular and Endovascular Monitor (EVEM): EVAR vs OPEN 2003-2012

WESTERN EUROPE PROCEDURES



Y-O-Y GROWTH RATE

	2003-04	2004-05	2005-06	2006-07	2007-08	2008-09	2009-10	2010-11	2011-12
EVAR	9%	39%	18%	1%	4%	4%	14%	15%	8%
Open	-5%	-9%	-5%	-4%	-3%	-10%	-8%	-11%	-34%

EVAR trial 30-day results – The Lancet

EVAR 5-year results – The Lancet

EVAR 10-year results – NEJM

BIBA MedTech Insights

15-year EVAR 1 follow up – benchmark for newer technologies

Roger Greenhalgh

Imperial College London